Abstract
Objective To evaluate the clinical value of serum prostate-specific antigen(PSA)and alkaline phosphatase(ALP) measurement in the diagnosis of prostate cancer patients with hone metastasis.Methods Serum PSA and ALP levels in 123 cases of prostate cancer patients, during which 58 ones have bone metastasis and the others do not have bone metastasis, was retrospectively analyzed to find the correlation between serum PSA ,ALP and bone metastasis. And use the bone scan as the diagnosis golden standard for bone metastasis. Results Both serum PSA and ALP levels in bone metastases patients were higher than the patients without bone metastases( P<0.05 ). The bone metastases incidence rate(45.5%) of the prostate cancer patients with a serum PSA ≥ 20 ug/L was higher than the incidence rate(1.63%) of the ones with serum PSA<20ug/L; the ones with a serum ALP ≥ 90 U/L which counted for 39.02% had a higher incidence rate of bone metastases than the ones with a serum ALP<90 U/L which counted for 8.13%.Conclusion For the definite prostate cancer patients without any treatment, to diagnose the bone metastasis early, nuclide bone scan is suggested as a routine detection, if the serum PSA ≥ 20 ug/L or the serum ALP ≥ 90 U/L. Key words: prostate cancer; bone metastasis: prostate-specific antigen; alkaline phosphatase
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
